BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival

被引：11

作者：

Barbosa Pagnano, Katia Borgia ^{[1
]}

Bendit, Israel ^{[2
]}

Boquimpani, Carla ^{[3
]}

De Souza, Carmino Antonio ^{[1
]}

Miranda, Eliana C. M. ^{[1
]}

Zalcberg, Ilana ^{[4
]}

Larripa, Irene ^{[5
]}

Nardinelli, Luciana ^{[2
]}

Silveira, Rosana Antunes ^{[1
]}

Fogliatto, Laura ^{[6
]}

Spector, Nelson ^{[7
]}

Funke, Vaneuza ^{[8
]}

Pasquini, Ricardo ^{[8
]}

Hungria, Vania ^{[9
]}

Chiattone, Carlos Sergio ^{[9
]}

Clementino, Nelma ^{[10
]}

Conchon, Monika ^{[11
]}

Beatriz Moiraghi, Elena ^{[12
]}

Lopez, Jose Luis ^{[13
]}

Pavlovsky, Carolina ^{[14
]}

Pavlovsky, Miguel A. ^{[14
]}

Cervera, Eduardo E. ^{[15
]}

Antonio Meillon, Luis ^{[16
]}

Simoes, Belinda ^{[17
]}

Hamerschlak, Nelson ^{[18
]}

Magarinos Bozzano, Alicia Helena ^{[19
]}

Mayta, Ernesto ^{[20
]}

Cortes, Jorge ^{[21
]}

Bengio, Raquel M. ^{[5
]}

机构：

[1] Univ Estadual Campinas, UNICAMP, Hemoctr, BR-13083878 Campinas, SP, Brazil

[2] Univ Sao Paulo, Lab Biol Tumoral, Sao Paulo, SP, Brazil

[3] Hemorio, Rio De Janeiro, RJ, Brazil

[4] Inst Nacl Canc, Rio De Janeiro, RJ, Brazil

[5] Acad Nacl Med Buenos Aires, Inst Invest Hematol, Buenos Aires, DF, Argentina

[6] Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil

[7] Univ Fed Rio de Janeiro, Rio De Janeiro, RJ, Brazil

[8] Univ Fed Parana, BR-80060000 Curitiba, Parana, Brazil

[9] Santa Casa Sao Paulo, Sao Paulo, SP, Brazil

[10] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil

[11] Hosp Santa Marcelina, Sao Paulo, SP, Brazil

[12] Hosp Ramos Mejia, Buenos Aires, DF, Argentina

[13] Banco Municipal Sangre DC, Caracas, Venezuela

[14] FUNDALEU, Buenos Aires, DF, Argentina

[15] INCAN, Mexico City, DF, Mexico

[16] Ctr Med Nacl Siglo XXI, Mexico City, DF, Mexico

[17] Univ Sao Paulo, BR-14049 Ribeirao Preto, SP, Brazil

[18] Hosp Israelita Albert Einstein, Sao Paulo, SP, Brazil

[19] Hosp Maciel, Montevideo, Uruguay

[20] Inst Oncol Nacl, Panama City, Panama

[21] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

CANCER INVESTIGATION | 2015年 / 33卷 / 09期

基金：

巴西圣保罗研究基金会;

关键词：

Chronic myeloid leukemia; BCR-ABL mutations; Imatinib; Resistance; Tyrosine kinase inhibitors; CHRONIC MYELOGENOUS LEUKEMIA; GIMEMA WORKING PARTY; DOMAIN MUTATIONS; EUROPEAN-LEUKEMIANET; IMATINIB RESISTANCE; MANAGEMENT; THERAPY; CML; RECOMMENDATIONS; MESYLATE;

D O I：

10.3109/07357907.2015.1065499

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This is the largest Latin American study of BCR-ABL mutations in chronic myeloid leukemia (CML) patients, resistant to imatinib (IM). In 195/467 (41%) patients, mutations were detected. The most frequent mutation was T315I (n=31, 16%). Progression-free (PFS) and overall survival (OS) at 5 years were lower in patients with BCR-ABL mutations (43% vs. 65%, p=0.07 and 47% vs. 72%, p=0.03, respectively) and in those with the T315I mutation (p=0.003 and p=0.03). OS and PFS were superior in subgroup who switched to second generation inhibitors (SGIs) after IM failure (OS: 50% vs. 39% p=0.01; PFS: 48% vs. 30% p=0.02). BCR-ABL mutations conferred a significant poor prognosis in CML patients.

引用

页码：451 / 458

页数：8

共 50 条

[1] Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia
Hyewon Lee
Igor Novitzky Basso
Dennis Dong Hwan Kim
International Journal of Hematology, 2021, 113 : 632 - 641
[2] Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia
Lee, Hyewon
Basso, Igor Novitzky
Kim, Dennis Dong Hwan
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (05) : 632 - 641
[3] BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia
Schiffer, Charles A.
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (03): : 258 - 265
[4] Heterocyclic Compounds as Bcr-Abl Tyrosine Kinase Inhibitors Against Chronic Myeloid Leukemia
Gado, Sarah
Hassan, Mohammed Al-Kassim
Kisla, Mehmet Murat
Ates-Alagoz, Zeynep
MEDICINAL CHEMISTRY, 2024,
[5] Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia
Verma, Dushyant
Fava, Carmen
Kantarjian, Hagop
Cortes, Jorge
AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (04) : 256 - 257
[6] Impact of BCR-ABL mutations on patients with chronic myeloid leukemia
Hochhaus, Andreas
La Rosee, Paul
Mueller, Martin C.
Ernst, Thomas
Cross, Nicholas C. P.
CELL CYCLE, 2011, 10 (02) : 250 - 260
[7] BCR-ABL Mutations in Chronic Myeloid Leukemia
Ernst, Thomas
La Rosee, Paul
Mueller, Martin C.
Hochhaus, Andreas
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2011, 25 (05) : 997 - +
[8] Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
Goldman, JM
Melo, JV
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14): : 1084 - 1086
[9] Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors
Cortes, Jorge
Jabbour, Elias
Kantarjian, Hagop
Yin, C. Cameron
Shan, Jianqin
O'Brien, Susan
Garcia-Manero, Guillermo
Giles, Francis
Breeden, Megan
Reeves, Nubia
Wierda, William G.
Jones, Dan
BLOOD, 2007, 110 (12) : 4005 - 4011
[10] Discontinuation of BCR-ABL tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a retrospective study
Iino, Masaki
ANNALS OF ONCOLOGY, 2017, 28

← 1 2 3 4 5 →